Ownership and insider activity for MediciNova, Inc. (MNOV): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions.
Price
| Price | $2.52 |
| Market Cap | $124M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-23 | Nagao Hideki | A-Award | 44,500 | $61K |
| 2026-06-23 | Lemerond Nicole | A-Award | 44,500 | $61K |
| 2026-06-23 | BEAVER CAROLYN | A-Award | 44,500 | $61K |
| 2026-01-16 | Matsuda Kazuko | A-Award | 350,000 | $735K |
| 2026-01-16 | IWAKI YUICHI | A-Award | 450,000 | $945K |
| 2025-06-17 | Nagao Hideki | A-Award | 20,000 | $25K |
| 2025-06-17 | Lemerond Nicole | A-Award | 20,000 | $25K |
| 2025-06-17 | BEAVER CAROLYN | A-Award | 20,000 | $25K |
| 2025-02-12 | Nagao Hideki | A-Award | 24,500 | $45K |
| 2025-02-12 | Matsuda Kazuko | A-Award | 100,000 | $184K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.1M | $28.0M | $62.3M | $63.8M | $60.0M | $71.4M | $18.5M | $51.0M | $40.4M | $30.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | $40.0M | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $24.7M | $28.3M | $62.8M | $64.3M | $60.7M | $72.0M | $59.0M | $51.2M | $41.1M | $31.0M |
| Property, Plant & Equipment | $90717 | $62886 | $53134 | $40550 | $226557 | $881780 | $674764 | $621206 | $382411 | $192569 |
| Goodwill | $9.6M | $9.6M | $9.6M | $9.6M | $9.6M | $9.6M | $9.6M | $9.6M | $9.6M | $9.6M |
| Intangible Assets | $4.8M | $4.8M | $4.8M | $4.8M | $4.8M | $4.8M | $4.8M | $4.8M | $4.8M | $4.8M |
| Total Assets | $39.8M | $43.4M | $77.2M | $79.2M | $75.4M | $87.4M | $74.2M | $66.3M | $55.9M | $45.6M |
| Accounts Payable | $367275 | $1.5M | $616753 | $451326 | $616629 | $402740 | $424646 | $1.0M | $1.1M | $624995 |
| Short-term Debt | 0 | 0 | 0 | $216768 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.6M | $2.9M | $2.2M | $2.2M | $2.2M | $2.8M | $3.2M | $3.3M | $3.0M | $3.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $5.3M | $4.8M | $4.1M | $4.3M | $4.1M | $3.7M | $3.9M | $3.9M | $3.4M | $4.0M |
| Retained Earnings | -$330.3M | -$341.5M | -$356.1M | -$369.1M | -$382.9M | -$393.1M | -$407.1M | -$415.7M | -$426.8M | -$438.7M |
| Total Equity | $34.5M | $38.6M | $73.1M | $74.9M | $71.3M | $83.7M | $70.2M | $62.4M | $52.5M | $41.6M |
| Total Debt | $967000 | 0 | $27.2M | $399347 | $186028 | $826639 | $681123 | $215926 | $193769 | $194331 |
| Net Debt | -$23.2M | -$28.0M | -$35.1M | -$63.4M | -$59.9M | -$70.6M | -$57.8M | -$50.8M | -$40.2M | -$30.6M |
| Working Capital | $23.1M | $25.4M | $60.6M | $62.1M | $58.5M | $69.2M | $55.8M | $47.9M | $38.1M | $27.2M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 8.75 |
Profitability
| Return on Equity | -26.51% |
| Return on Invested Capital | -31.53% |
| Return on Assets | -26.59% |
| Gross Margin | 42.39% |
| Operating Margin | -1287.41% |
| Net Margin | -1168.20% |
Related companies: ACRV · BMEA · CBUS · FBIO · IMUX · PMVP · RLMD
Explore sector: Healthcare · Biotechnology
More sections of MNOV: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks